Cellumed Co.,Ltd.

KOSDAQ:A049180 Stock Report

Market Cap: ₩84.0b

CellumedLtd Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for CellumedLtd.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Medical Equipment earnings growth44.1%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

No updates

Recent updates

Analysis Article • Dec 18

Cellumed Co.,Ltd. (KOSDAQ:049180) Looks Inexpensive But Perhaps Not Attractive Enough

You may think that with a price-to-sales (or "P/S") ratio of 0.3x Cellumed Co.,Ltd. ( KOSDAQ:049180 ) is a stock worth...
Analysis Article • Oct 15

We Think CellumedLtd (KOSDAQ:049180) Has A Fair Chunk Of Debt

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analysis Article • Aug 18

The Market Doesn't Like What It Sees From Cellumed Co.,Ltd.'s (KOSDAQ:049180) Revenues Yet As Shares Tumble 35%

KOSDAQ:A049180 1 Year Share Price vs Fair Value Explore CellumedLtd's Fair Values from the Community and select yours...
Analysis Article • Aug 18

Why Investors Shouldn't Be Surprised By Cellumed Co.,Ltd.'s (KOSDAQ:049180) 35% Share Price Plunge

Cellumed Co.,Ltd. ( KOSDAQ:049180 ) shareholders that were waiting for something to happen have been dealt a blow with...
Analysis Article • Jun 18

Health Check: How Prudently Does CellumedLtd (KOSDAQ:049180) Use Debt?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Analysis Article • Apr 13

Little Excitement Around Cellumed Co.,Ltd.'s (KOSDAQ:049180) Revenues As Shares Take 26% Pounding

To the annoyance of some shareholders, Cellumed Co.,Ltd. ( KOSDAQ:049180 ) shares are down a considerable 26% in the...
Analysis Article • Feb 20

Revenues Working Against Cellumed Co.,Ltd.'s (KOSDAQ:049180) Share Price

Cellumed Co.,Ltd.'s ( KOSDAQ:049180 ) price-to-sales (or "P/S") ratio of 0.8x might make it look like a buy right now...
Analysis Article • Nov 01

Benign Growth For Cellumed Co.,Ltd. (KOSDAQ:049180) Underpins Stock's 35% Plummet

Cellumed Co.,Ltd. ( KOSDAQ:049180 ) shares have retraced a considerable 35% in the last month, reversing a fair amount...
Analysis Article • Aug 27

Cellumed Co.,Ltd.'s (KOSDAQ:049180) Low P/S No Reason For Excitement

Cellumed Co.,Ltd.'s ( KOSDAQ:049180 ) price-to-sales (or "P/S") ratio of 0.7x might make it look like a buy right now...
Analysis Article • Jun 04

CellumedLtd (KOSDAQ:049180) Has Debt But No Earnings; Should You Worry?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as CellumedLtd has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

KOSDAQ:A049180 - Analysts future estimates and past financials data (KRW Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
3/31/2026124,366-2,451-6,450-6,369N/A
12/31/2025140,194-2,236-4,147-3,860N/A
9/30/2025148,549-21,297-4,661-4,132N/A
6/30/2025144,540-31,208-8,535-7,269N/A
3/31/2025142,118-31,383-8,034-6,120N/A
12/31/2024129,140-31,545-2,202-419N/A
9/30/2024119,645-30,916-5,933-3,140N/A
6/30/2024111,867-30,238-8,219-5,595N/A
3/31/2024102,157-33,351-9,158-3,750N/A
12/31/202395,553-37,280-12,669-5,374N/A
9/30/202395,474-20,081-12,116-5,730N/A
6/30/2023101,425-19,700-8,249-1,443N/A
3/31/2023112,943-13,167-10,780-3,915N/A
12/31/2022122,085-5,368-14,042-8,287N/A
9/30/2022126,0157,460-14,647-9,079N/A
6/30/2022121,36111,339-17,768-11,684N/A
3/31/2022109,83210,257-8,464-5,571N/A
12/31/202199,9188,010-4,938-2,670N/A
9/30/202184,5642,931-7421,365N/A
6/30/202182,0101244,3294,974N/A
3/31/202177,548-38-1,926-1,254N/A
12/31/202073,188-1,078-3,674-2,556N/A
9/30/202066,694-31,951-8,091-3,505N/A
6/30/202045,315-34,397-8,091-2,894N/A
3/31/202029,904-35,762-6,562-1,464N/A
12/31/201917,921-36,422N/A473N/A
9/30/201910,983-17,881N/A-1,199N/A
6/30/201910,156-15,428N/A296N/A
3/31/20199,311-7,012N/A-2,741N/A
12/31/20189,915-7,890N/A-1,781N/A
9/30/201813,782969N/A-1,704N/A
6/30/201815,763-783N/A-4,531N/A
3/31/201818,279-8,541N/A-3,008N/A
12/31/201719,904-6,302N/A-5,074N/A
9/30/201716,388-11,050N/A-4,837N/A
6/30/201714,696-10,624N/A-4,623N/A
3/31/201712,076-34,743N/A-4,953N/A
12/31/20169,814-36,588N/A-4,765N/A
9/30/201612,815-35,616N/A-790N/A
6/30/201612,563-38,046N/A-4,484N/A
3/31/201615,415-13,630N/A-6,479N/A
12/31/201517,731-11,345N/A-4,618N/A
9/30/201514,764-19,493N/A-9,521N/A
6/30/201517,681-15,940N/A-7,626N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if A049180's forecast earnings growth is above the savings rate (3.1%).

Earnings vs Market: Insufficient data to determine if A049180's earnings are forecast to grow faster than the KR market

High Growth Earnings: Insufficient data to determine if A049180's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if A049180's revenue is forecast to grow faster than the KR market.

High Growth Revenue: Insufficient data to determine if A049180's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if A049180's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/13 11:54
End of Day Share Price 2026/03/16 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Cellumed Co.,Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.